{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-005338","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.857385+00:00","generated_at":"2026-05-26T00:58:10.555548+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cassava Sciences licenses Yale simufilam patent for TSC-related seizures; up to $4.5M milestones","bullets":["Exclusive worldwide license to issued US method of treatment patent (US 12,186,307) for simufilam in TSC-related epilepsy and other indications.","Financial terms: nominal upfront, up to $4.5M in clinical/regulatory/commercial milestones, tiered low-to-mid single-digit % royalties on net sales.","Based on Yale research (Bordey et al., Science Translational Medicine 2020) showing simufilam reduced seizure frequency in an animal model.","Cassava to prioritize initial development on TSC-related seizures and plans preclinical studies with the TSC Alliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-005338","json":"https://secwatch.observer/filing/0001437749-25-005338.json","markdown":"https://secwatch.observer/filing/0001437749-25-005338.md","text":"https://secwatch.observer/filing/0001437749-25-005338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000143774925005338/0001437749-25-005338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000143774925005338/sava20250224_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T00:58:10.555548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}